Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 20,800 shares, a growth of 61.2% from the September 30th total of 12,900 shares. Currently, 3.4% of the company’s shares are short sold. Based on an average daily volume of 27,500 shares, the short-interest ratio is presently 0.8 days.
Sonnet BioTherapeutics Stock Performance
Shares of NASDAQ SONN opened at $6.01 on Friday. Sonnet BioTherapeutics has a one year low of $4.37 and a one year high of $18.72. The business has a 50-day moving average price of $2.69 and a two-hundred day moving average price of $1.81.
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.06. As a group, analysts anticipate that Sonnet BioTherapeutics will post -12.88 earnings per share for the current year.
Analysts Set New Price Targets
View Our Latest Stock Analysis on Sonnet BioTherapeutics
Hedge Funds Weigh In On Sonnet BioTherapeutics
An institutional investor recently bought a new position in Sonnet BioTherapeutics stock. Armistice Capital LLC acquired a new stake in shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 272,000 shares of the company’s stock, valued at approximately $255,000. Armistice Capital LLC owned about 8.74% of Sonnet BioTherapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 9.45% of the company’s stock.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
Featured Articles
- Five stocks we like better than Sonnet BioTherapeutics
- 3 Tickers Leading a Meme Stock Revival
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Why Are Stock Sectors Important to Successful Investing?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the S&P 500 and How It is Distinct from Other Indexes
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.